News
 

Air pollution may be another environmental risk factor for developing multiple sclerosis (MS), new research suggests.

The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches.

Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)‐approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes.

Researchers are taking a closer look at whether the diabetes medication metformin might convey benefit in patients with both Parkinson's disease (PD) and diabetes - and are finding some positive signals.

Lowering blood pressure (BP) with antihypertensive agents is linked to a significant reduction in the risk of dementia or cognitive impairment, new research suggests.

Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are...

Adults who develop amyotrophic lateral sclerosis (ALS) metabolize metals differently than those who do not develop the neurodegenerative disease, and this shows up in teeth during childhood, new research suggests.

To determine whether women with multiple sclerosis (MS) diagnosed according to current criteria are at an increased risk of postpartum relapses and to assess whether this risk is modified by breastfeeding or MS disease-modifying therapies (DMTs), the authors (Neurology. 2020 May 5;94(18):e1939-e1949) examined the electronic health records (EHRs) of...

Migraine and stroke are two common and heterogeneous neurovascular disorders responsible for a significant burden for those affected and a great economic cost for the society.